Market Snapshot
| Study Period: | 2019-2027 |
| Base Year: | 2021 |
| Fastest Growing Market: | Asia Pacific |
| Largest Market: | North America |
| CAGR: | 3 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The global pregabalin market is projected to witness a CAGR of nearly 3% over the forecast period.
During the pandemic many big pharma giants had sought collaborations and approvals to come up with a vaccine in the market space, to prevent the spread of COVID-19 as soon as possible. The focus of pharma giants on the vaccines and treatment of COVID-19 has created an impact on the other drug manufacturing and supply.
Additionally, in December 2020, as per the National Library of Medicine study, diabetic patients with microvascular complications have been shown to develop more serious complications from infection with COVID-19 and may be predisposed to the development or worsening of neuropathy. Thus, patients with diabetic neuropathy are facing more serious complications when getting contracting COVID-19, thus making a significant impact on the market.
The pandemic has also impacted generic manufacturers, which are supplying most of the market volume, due to supply chain issues. This has decreased the production rates. However, this has driven up the prices of drugs in the short term. Furthermore, the innovator drug manufacturers have filled the supply gap, leading to a relatively lower impact on the market. For instance, In December 2020, Sawai launched Japan’s first generic version of the Lyrica pregabalin brand. Similarly, In May 2020, Neuraxpharm launched the generic version of Lyrica in the United Kingdom. Thus, increasing product launches during a pandemic are responsible for the significant impact on the market during COVID-19.
The market is primarily driven by the growing prevalence of epilepsy, neuropathic pain, and related disorders, globally. Additionally, the growing geriatric population, coupled with the increasing prevalence of diabetes, neuropathic pain, fibromyalgia, and others, is anticipated to fuel the market growth over the forecast period. According to the recent updates by the World Health Organization (WHO), 2021, there are an estimated 50 million people worldwide with epilepsy, of whom up to 80% live in resource-poor countries with little or no access to treatment or medical services. Moreover, about 80% of people with epilepsy live in middle- and low-income countries.
Moreover, the company’s efforts to broaden the applications of pregabalin through R&D are expected to boost the market growth. However, the FDA approval of generic versions of the drug increases the availability of the drug but decreases the market revenue. Moreover, the availability of alternatives, adverse effects, and stringent regulatory policies are expected to hamper the growth of pregabalin.
Scope of the Report
Pregabalin is an anti-convulsive drug used to treat epilepsy, fibromyalgia, neuropathic pain, and other related disorders. It acts by reducing nervous activity and reduces pain. The pregabalin market is segmented by product (capsules, oral solutions, and tablets), application (epilepsy, neuropathic pain, anxiety disorder, and other applications), and geography (North America, Europe, Asia-Pacific, and the Rest of the World). The report offers the value (in USD million) for the above segments.
| By Product | |
| Capsules | |
| Oral Solutions | |
| Other Products |
| By Application | |
| Epilepsy | |
| Neuropathic Pain | |
| Anxiety Disorder | |
| Other Applications |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| Rest of The World |
Key Market Trends
Neuropathic Pain Application Segment is Expected to Witness Growth Over the Forecast Period
Neuropathic pain often refers to burning or shooting pain. The damage to nerves usually causes it. Pregabalin is used to reduce neuropathic pain by blocking the pain signals. The increasing cases of neuropathic pain and growing risk factors, such as diabetes and HIV, are anticipated to fuel the market growth. As per the International Diabetes Federation updated in 2021, approximately 537 million adults (20-79 years) are living with diabetes. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045.
Moreover, as per the National Institute of Health 2021 article, globally, diabetic polyneuropathy (DPN) has a lifetime prevalence of nearly 50%, and it is the most common diabetic complication. Around 20 to 30% of patients with diabetic Neuropathy suffer from neuropathic pain. Thus, increasing diabetic neuropathy cases is responsible for increasing demand for Pregabalin which is fueling the growth of the market.
Additionally, Viatris Inc's Lyrica (pregabalin) patent expiry in December 2020 has increased the market share for generic drug manufacturers in the market. Furthermore, continuous R&D in widening the applications of pregabalin in different disease interventions, coupled with recent product launches, is anticipated to boost the market growth. Due to the success of Viatris Inc's Lyrica, many manufacturers have applied for pregabalin production, worldwide. Moreover, the increasing number of geriatric populations with neurological disorders is anticipated to fuel the pregabalin market growth over the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Dominate the Pregabalin Market
Among the regional segment, North America is expected to have significant market growth over the forecast period. This growth is attributed to the growing prevalence of chronic diseases, well-established healthcare infrastructure, and the high adoption of advanced technologies and government initiatives to mandate the maintenance of health records.
For instance, In August 2021, As per the Centers for Disease Control and Prevention (CDC), around 3.4 million people in the United States live with seizures, including 470,000 children. Moreover, four out of 10 people with epilepsy continue to experience uncontrolled seizures despite all available treatments, while many more experience less than optimal seizure control. The increasing acceptance of progressive technologies and proliferating initiatives by the government to authorize the maintenance of health records are further propelling the growth of this segment.
Additionally, due to the increased prevalence of disorders such as neuropathy, diabetes, and Human Immuno Virus, pregabalin is in great demand among the elderly. For instance, As per an American study in 2020, Peripheral neuropathy affects 50% of diabetic individuals. While Neuropathy is predicted to be present in 7.5% of diabetic individuals at the time of diagnosis. More than half of all cases of polyneuropathy are distal symmetric polyneuropathy. These are the major factor that propels the growth of this region in the global market during the forecast period.
Thus, the aforementioned factors are driving the growth of the target region.
To understand geography trends, Download Sample Report
Competitive Landscape
The global pregabalin market is moderately consolidated with a limited number of market players. However, the market is anticipated to be intense due to the recent approvals of generic manufacturers. Market players are focusing on new product launches and geographical expansions to increase their market share. The key market players operating in the market include Viatris Inc, Amneal Pharmaceuticals LLC, InvaGen Pharmaceuticals, Zydus Cadila, Sciegen Pharmaceuticals Inc., Teva Pharmaceuticals, Rising Pharmaceuticals Inc., MSN Laboratories Ltd, Dr. Reddy's Laboratories and Cipla Limited.
RECENT DEVELOPMENTS
- In November 2021, Cadila Healthcare (Zydus Cadila) inked a manufacturing license and technology transfer agreement with Enzychem Lifesciences (Enzychem) of the Republic of Korea for its plasmid DNA-based Covid-19- ZyCoV-D. As per the terms of the agreement, Zydus Cadila will offer a manufacturing license and deliver the plasmid DNA vaccine technology to Enzychem Lifesciences. Both CHL and Enzychem think that this partnership will result in an approximated production of 80 million or more doses of the Plasmid DNA vaccine in 2022, as per a statement from Cadila Healthcare.
- In November 2021, Cipla declared the introduction of Spirofy, India's earliest pneumotach-based portable, wireless Spirometer, on World COPD Day. With this kick-off, the firm targets to transform Obstructive Airway Disease (OAD) diagnosis, in line with its aspiration to build up its position as the lung leader in India. This is a portion of the firm’s 'LungAttack' campaign that attempts to propel awareness regarding COPD and inspire early diagnosis.
- In March 2021, Lupin Limited (Lupin), declared the introduction of the authorized generic version of Alinia (nitazoxanide) Tablets, 500 mg of Romark Laboratories, L.C. Nitazoxanide Tablets, 500 mg, are indicated in the treatment of diarrhea brought about by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and more. Nitazoxanide Tablets, 500 mg (RLD: Alinia) had approximated annual sales of USD 56 million in the U.S. (IQVIA MAT January 2021).
Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Epilepsy and Related Disorders
4.2.2 Rising Geriatric Population with Neuropathic Pain
4.3 Market Restraints
4.3.1 Stringent Regulatory Policies
4.3.2 Availability of Alternatives and Adverse Effects Related to Pregabalin
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product
5.1.1 Capsules
5.1.2 Oral Solutions
5.1.3 Other Products
5.2 By Application
5.2.1 Epilepsy
5.2.2 Neuropathic Pain
5.2.3 Anxiety Disorder
5.2.4 Other Applications
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Rest of Asia Pacific
5.3.4 Rest of The World
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Cipla Limited
6.1.2 Dr. Reddy's Laboratories
6.1.3 MSN Laboratories Ltd
6.1.4 Rising Pharmaceuticals Inc.
6.1.5 Teva Pharmaceuticals
6.1.6 Sciegen Pharmaceuticals Inc.
6.1.7 Zydus Cadila
6.1.8 InvaGen Pharmaceuticals
6.1.9 Amneal Pharmaceuticals LLC
6.1.10 Viatris Inc
*List Not Exhaustive7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Pregabalin Market market is studied from 2019 - 2027.
What is the growth rate of Global Pregabalin Market?
The Global Pregabalin Market is growing at a CAGR of 3% over the next 5 years.
Which region has highest growth rate in Global Pregabalin Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Pregabalin Market?
North America holds highest share in 2021.
Who are the key players in Global Pregabalin Market?
Teva Pharmaceuticals, Cipla Limited , Medley Pharmaceuticals Limited , Viatris Inc. , Amneal Pharmaceuticals LLC are the major companies operating in Global Pregabalin Market.
